SCHEMBL13157595

SCHEMBL13157595

CN(O)C(=O)N1CCC(c2cc(-c3ccccc3)n(-c3ccccc3)n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 6/20 0.51
▸ FAAH O00519 1/20 0.51
▸ RPA1 P27694 2/20 0.46
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ CNR1 P21554 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ KCNJ6 P48051 3/20 0.42
▸ KCNJ3 P48549 3/20 0.42
▸ LMNA P02545 2/20 0.41
▸ MALT1 Q9UDY8 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3098701 0.91 KCNJ6 (0.51) MGLLFAAHRPA1KCNJ6KCNJ3
SCHEMBL3103064 0.88 MGLL (0.46) MGLLFAAHRPA1MALT1
SCHEMBL3105238 0.88 KDM1A (0.46) MGLLKCNJ6KCNJ3MALT1SMN1; SMN2
SCHEMBL3100407 0.85 PTGS2 (0.50) MGLLRPA1KCNJ6KCNJ3MALT1
SCHEMBL13158124 0.84 RPA1 (0.46) MGLLFAAHRPA1KCNJ6KCNJ3
SCHEMBL13158111 0.83 FAAH (0.47) MGLLFAAHRPA1RAB9AKCNJ6
SCHEMBL3104741 0.81 CCKAR (0.47) ALOX5
SCHEMBL3104707 0.81 MGLL (0.54) MGLLRPA1KCNJ6KCNJ3MALT1
SCHEMBL13157576 0.81 MGLL (0.45) MGLLMALT1
SCHEMBL3105667 0.81 MGLL (0.54) MGLLRPA1KCNJ6KCNJ3MALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 — — US disclosed
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF UROD, UTS2R, SLC14A1 MGLL 1894/4885FAAH 1533/4885RPA1 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback